Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden

[1]  M. Youle,et al.  Health Economics in HIV Disease , 2012, PharmacoEconomics.

[2]  Scott R. Smith,et al.  Economic costs to business of the HIV/AIDS epidemic , 2012, PharmacoEconomics.

[3]  J. Oliva,et al.  Indirect costs in ambulatory patients with HIV/AIDS in Spain , 2012, PharmacoEconomics.

[4]  J. Montaner,et al.  Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting , 2009, HIV medicine.

[5]  A. Blaxhult,et al.  Increase of reported HIV infections in Sweden. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  J. Albert,et al.  Antiretroviral treatment of HIV infection: Swedish recommendations 2007 , 2007, Scandinavian journal of infectious diseases.

[7]  R. Weinstein,et al.  The cost of care for patients with HIV from the provider economic perspective. , 2006, AIDS patient care and STDs.

[8]  A. Blaxhult,et al.  Antiretroviral treatment of HIV infection: Swedish recommendations 2005 , 2006, Scandinavian journal of infectious diseases.

[9]  M. Gill,et al.  The high cost of medical care for patients who present late (CD4<200 cells/μL) with HIV infection , 2004, HIV medicine.

[10]  J. Graf von der Schulenburg,et al.  Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. , 2002, European journal of medical research.

[11]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.

[12]  M. Youle,et al.  Health economics in HIV disease. A review of the European literature. , 1999, PharmacoEconomics.